{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T06:13:10Z","timestamp":1793772790121,"version":"4.6.1"},"reference-count":48,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2019,4,11]],"date-time":"2019-04-11T00:00:00Z","timestamp":1554940800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s40425-019-0588-y","type":"journal-article","created":{"date-parts":[[2019,4,11]],"date-time":"2019-04-11T05:20:24Z","timestamp":1554960024000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":104,"title":["Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity"],"prefix":"10.1136","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1239-1603","authenticated-orcid":false,"given":"Giuseppe","family":"Minniti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitri","family":"Anzellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Reverberi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Carlo Antonini","family":"Cappellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Marchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Bianciardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Bozzao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Osti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Carlo","family":"Gentile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,4,11]]},"reference":[{"key":"588_CR1","doi-asserted-by":"publisher","first-page":"e486","DOI":"10.1016\/S1470-2045(15)00141-2","volume":"16","author":"T Ajithkumar","year":"2015","unstructured":"Ajithkumar T, Parkinson C, Fife K, et al. Evolving treatment options for melanoma brain metastases. Lancet Oncol. 2015;16:e486\u201397.","journal-title":"Lancet Oncol"},{"key":"588_CR2","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1200\/JCO.2010.30.1655","volume":"29","author":"M Kocher","year":"2011","unstructured":"Kocher M, Soffietti R, Abacioglu U, et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol. 2011;29:134\u201341.","journal-title":"J Clin Oncol"},{"key":"588_CR3","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1001\/jama.2016.9839","volume":"316","author":"PD Brown","year":"2016","unstructured":"Brown PD, Jaeckle K, Ballman KV, et al. Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases: A Randomized Clinical Trial. JAMA. 2016;316:401\u20139.","journal-title":"JAMA"},{"key":"588_CR4","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/S0360-3016(01)02772-9","volume":"52","author":"C Yu","year":"2002","unstructured":"Yu C, Chen JC, Apuzzo ML, et al. Metastatic melanoma to the brain: prognostic factors after gamma knife radiosurgery. Int J Radiat Oncol Biol Phys. 2002;52:1277\u201387.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"588_CR5","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/j.ijrobp.2003.12.037","volume":"59","author":"U Selek","year":"2004","unstructured":"Selek U, Chang EL, Hassenbusch SJ 3rd, et al. Stereotactic radiosurgical treatment in 103 patients for 153 cerebral melanoma metastases. Int J Radiat Oncol Biol Phys. 2004;59:1097\u2013106.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"588_CR6","doi-asserted-by":"publisher","first-page":"8870","DOI":"10.1200\/JCO.2005.01.8747","volume":"23","author":"R Manon","year":"2005","unstructured":"Manon R, O'Neill A, Knisely J, et al. Phase II trial of radiosurgery for one to three newly diagnosed brain metastases from renal cell carcinoma, melanoma, and sarcoma: an Eastern Cooperative Oncology Group study (E 6397). J Clin Oncol. 2005;23:8870\u20136.","journal-title":"J Clin Oncol"},{"key":"588_CR7","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s11060-017-2394-z","volume":"132","author":"G Minniti","year":"2017","unstructured":"Minniti G, Paolini S, D'Andrea G, et al. Outcomes of postoperative stereotactic radiosurgery to the resection cavity versus stereotactic radiosurgery alone for melanoma brain metastases. J Neuro-Oncol. 2017;132:455\u201362.","journal-title":"J Neuro-Oncol"},{"key":"588_CR8","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/S1470-2045(17)30429-1","volume":"18","author":"MA Davies","year":"2017","unstructured":"Davies MA, Saiag P, Robert C, et al. Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol. 2017;18:863\u201373.","journal-title":"Lancet Oncol"},{"key":"588_CR9","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1470-2045(12)70090-6","volume":"13","author":"K Margolin","year":"2012","unstructured":"Margolin K, Ernstoff MS, Hamid O, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 2012;13:459\u201365.","journal-title":"Lancet Oncol"},{"key":"588_CR10","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1470-2045(16)30053-5","volume":"17","author":"SB Goldberg","year":"2016","unstructured":"Goldberg SB, Gettinger SN, Mahajan A, et al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2016;17:976\u201383.","journal-title":"Lancet Oncol"},{"key":"588_CR11","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/S1470-2045(18)30139-6","volume":"19","author":"GV Long","year":"2018","unstructured":"Long GV, Atkinson V, Lo S, Sandhu S, et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicenter randomised phase 2 study. Lancet Oncol. 2018;19:672\u201381.","journal-title":"Lancet Oncol"},{"key":"588_CR12","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/NEJMoa1805453","volume":"379","author":"HA Tawbi","year":"2018","unstructured":"Tawbi HA, Forsyth PA, Algazi A, et al. Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. N Engl J Med. 2018;379:722\u201330.","journal-title":"N Engl J Med"},{"key":"588_CR13","doi-asserted-by":"crossref","unstructured":"Lehrer EJ, Peterson J, Brown PD, et al. Treatment of brain metastases with stereotactic radiosurgery and immune checkpoint inhibitors: An international metanalysis of individual patient data. Radiother Oncol. 2018.","DOI":"10.1016\/j.ijrobp.2018.06.343"},{"key":"588_CR14","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1016\/j.ijrobp.2016.03.013","volume":"95","author":"G Minniti","year":"2016","unstructured":"Minniti G, Scaringi C, Paolini S, et al. Single-Fraction Versus Multifraction (3 \u00d7 9 Gy) Stereotactic Radiosurgery for Large (>2 cm) Brain Metastases: A Comparative Analysis of Local Control and Risk of Radiation-Induced Brain Necrosis. Int J Radiat Oncol Biol Phys. 2016;95:1142\u20138.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"588_CR15","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1201\/b13224-9","volume-title":"Basic Clinical Radiobiology","author":"M Joiner","year":"2009","unstructured":"Joiner M. Quantifying cell kill and survival. In: Joiner M, Van der Kogel A, editors. Basic Clinical Radiobiology. 4th ed. London: Hodder Arnold; 2009. p. 102\u201319.","edition":"4"},{"key":"588_CR16","doi-asserted-by":"publisher","first-page":"612","DOI":"10.3389\/fonc.2018.00612","volume":"8","author":"ZS Buchwald","year":"2018","unstructured":"Buchwald ZS, Wynne J, Nasti TH, Zhu S, Mourad WF, Yan W, Gupta S, Khleif SN, Khan MK. Radiation, Immune Checkpoint Blockade and the Abscopal Effect: A Critical Review on Timing. Dose and Fractionation Front Oncol. 2018;8:612.","journal-title":"Dose and Fractionation Front Oncol"},{"key":"588_CR17","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1001\/jamaoncol.2015.2756","volume":"1","author":"S Maria De","year":"2015","unstructured":"De Maria S, Golden EB, Formenti SC. Role of Local Radiation Therapy in Cancer Immunotherapy. JAMA Oncol. 2015;1:1325\u201332.","journal-title":"JAMA Oncol"},{"key":"588_CR18","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1200\/JCO.2015.64.0391","volume":"34","author":"FS Hodi","year":"2016","unstructured":"Hodi FS, Hwu WJ, Kefford R, et al. Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. J Clin Oncol. 2016;34:1510\u20137.","journal-title":"J Clin Oncol"},{"key":"588_CR19","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer"},{"key":"588_CR20","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s00259-014-2886-4","volume":"42","author":"F Cicone","year":"2015","unstructured":"Cicone F, Minniti G, Romano A, et al. Accuracy of F-DOPA PET and perfusion-MRI for differentiating radionecrotic from progressive brain metastases after radiosurgery. Eur J Nucl Med Mol Imaging. 2015;42:103\u201311.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"588_CR21","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1200\/JCO.2011.38.0527","volume":"30","author":"PW Sperduto","year":"2012","unstructured":"Sperduto PW, Kased N, Roberge D, et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol. 2012;30:419\u201325.","journal-title":"J Clin Oncol"},{"key":"588_CR22","doi-asserted-by":"publisher","first-page":"227","DOI":"10.3171\/2012.5.JNS111929","volume":"117","author":"JP Knisely","year":"2016","unstructured":"Knisely JP, Yu JB, Flanigan J, et al. Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. J Neurosurg. 2016;117:227\u201333.","journal-title":"J Neurosurg"},{"key":"588_CR23","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.ijrobp.2015.01.004","volume":"92","author":"AP Kiess","year":"2015","unstructured":"Kiess AP, Wolchok JD, Barker CA, et al. Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment. Int J Radiat Oncol Biol Phys. 2015;92:368\u201375.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"588_CR24","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1093\/annonc\/mdv622","volume":"27","author":"KA Ahmed","year":"2016","unstructured":"Ahmed KA, Stallworth DG, Kim Y, et al. Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy. Ann Oncol. 2016;27:434\u201341.","journal-title":"Ann Oncol"},{"key":"588_CR25","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1002\/cncr.30138","volume":"122","author":"JM Qian","year":"2016","unstructured":"Qian JM, Yu JB, Kluger HM, Chiang VL. Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery. Cancer. 2016;122:3051\u20138.","journal-title":"Cancer."},{"key":"588_CR26","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.ejca.2017.01.007","volume":"75","author":"ES Choong","year":"2017","unstructured":"Choong ES, Lo S, Drummond M, et al. Survival of patients with melanoma brain metastasis treated with stereotactic radiosurgery and active systemic drug therapies. Eur J Cancer. 2017;75:169\u201378.","journal-title":"Eur J Cancer"},{"key":"588_CR27","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.3171\/2016.9.JNS161585","volume":"127","author":"O Cohen-Inbar","year":"2017","unstructured":"Cohen-Inbar O, Shih HH, Xu Z, Schlesinger D, Sheehan JP. The effect of timing of stereotactic radiosurgery treatment of melanoma brain metastases treated with ipilimumab. J Neurosurg. 2017;127:1007\u201314.","journal-title":"J Neurosurg"},{"key":"588_CR28","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ejca.2017.07.017","volume":"84","author":"C Gaudi-Marqueste","year":"2017","unstructured":"Gaudi-Marqueste C, Dussouil AS, Carron R, et al. Survival of melanoma patients treated with targeted therapy and immunotherapy after systematic upfront control of brain metastases by radiosurgery. Eur J Cancer. 2017;84:44\u201354.","journal-title":"Eur J Cancer"},{"key":"588_CR29","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1097\/COC.0000000000000199","volume":"40","author":"KR Patel","year":"2017","unstructured":"Patel KR, Shoukat S, Oliver DE, et al. Ipilimumab and Stereotactic Radiosurgery Versus Stereotactic Radiosurgery Alone for Newly Diagnosed Melanoma Brain Metastases. Am J Clin Oncol. 2017;40:444\u201350.","journal-title":"Am J Clin Oncol"},{"issue":"3","key":"588_CR30","doi-asserted-by":"publisher","first-page":"e1283461","DOI":"10.1080\/2162402X.2017.1283461","volume":"6","author":"Tijana Skrepnik","year":"2017","unstructured":"Skrepnik T, Sundararajan S, Cui H, Stea B. Improved time to disease progression in the brain in patients with melanoma brain metastases treated with concurrent delivery of radiosurgery and ipilimumab. Oncoimmunology. 2017;6(3).","journal-title":"OncoImmunology"},{"key":"588_CR31","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/j.ijrobp.2017.11.041","volume":"100","author":"L Chen","year":"2018","unstructured":"Chen L, Douglass J, Kleinberg L, et al. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma. Int J Radiat Oncol Biol Phys. 2018;100:916\u201325.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"588_CR32","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1097\/CMR.0000000000000413","volume":"28","author":"C Nardin","year":"2018","unstructured":"Nardin C, Mateus C, Texier M, et al. Tolerance and outcomes of stereotactic radiosurgery combined with anti-programmed cell death-1 (pembrolizumab) for melanoma brain metastases. Melanoma Res. 2018;28:111\u20139.","journal-title":"Melanoma Res"},{"key":"588_CR33","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s40425-017-0282-x","volume":"5","author":"ES Anderson","year":"2017","unstructured":"Anderson ES, Postow MA, Wolchok JD, et al. Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment. J Immunother Cancer. 2017;5:76.","journal-title":"J Immunother Cancer"},{"key":"588_CR34","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1097\/CMR.0b013e32835f3d90","volume":"23","author":"M Mathew","year":"2013","unstructured":"Mathew M, Tam M, Ott PA, et al. Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery. Melanoma Res. 2013;23:191\u20135.","journal-title":"Melanoma Res"},{"key":"588_CR35","doi-asserted-by":"publisher","first-page":"5514","DOI":"10.1158\/1078-0432.CCR-16-1673","volume":"23","author":"SJ Dovedi","year":"2017","unstructured":"Dovedi SJ, Cheadle EJ, Popple AL, et al. Fractionated Radiation Therapy Stimulates Antitumor Immunity Mediated by Both Resident and Infiltrating Polyclonal T-cell Populations when Combined with PD-1 Blockade. Clin Cancer Res. 2017;23:5514\u201326.","journal-title":"Clin Cancer Res"},{"key":"588_CR36","doi-asserted-by":"publisher","first-page":"5874","DOI":"10.4049\/jimmunol.1202612","volume":"190","author":"H Liang","year":"2013","unstructured":"Liang H, Deng L, Chmura S, et al. Radiation-induced equilibrium is a balance between tumor cell proliferation and T cell-mediated killing. J Immunol. 2013;190:5874\u201381.","journal-title":"J Immunol"},{"key":"588_CR37","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1158\/2326-6066.CIR-14-0196","volume":"3","author":"AB Sharabi","year":"2015","unstructured":"Sharabi AB, Nirschl CJ, Kochel CM, et al. Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen. Cancer Immunol Res. 2015;3:345\u201355.","journal-title":"Cancer Immunol Res"},{"key":"588_CR38","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1158\/1078-0432.728.11.2","volume":"11","author":"S Demaria","year":"2005","unstructured":"Demaria S, Kawashima N, Yang AM, et al. Immune-mediated inhibition of metastases following treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res. 2005;11:728\u201334.","journal-title":"Clin Cancer Res"},{"key":"588_CR39","doi-asserted-by":"publisher","first-page":"5379","DOI":"10.1158\/1078-0432.CCR-09-0265","volume":"15","author":"MZ Dewan","year":"2009","unstructured":"Dewan MZ, Galloway AE, Kawashima N, et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res. 2009;15:5379\u201388.","journal-title":"Clin Cancer Res"},{"key":"588_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15618","volume":"8","author":"C Vanpouille-Box","year":"2017","unstructured":"Vanpouille-Box C, Alard A, Aryankalayil MJ, et al. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat Commun. 2017;8:15618.","journal-title":"Nat Commun"},{"key":"588_CR41","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1056\/NEJMoa1112824","volume":"366","author":"MA Postow","year":"2012","unstructured":"Postow MA, Callahan MK, Barker CA, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012;366:925\u201331.","journal-title":"N Engl J Med"},{"key":"588_CR42","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1046028","volume":"4","author":"RA Chandra","year":"2015","unstructured":"Chandra RA, Wilhite TJ, Balboni TA, et al. A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab. Oncoimmunology. 2015;4:e1046028.","journal-title":"Oncoimmunology"},{"key":"588_CR43","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/S1470-2045(15)00054-6","volume":"16","author":"EB Golden","year":"2015","unstructured":"Golden EB, Chhabra A, Chachoua A, et al. Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial. Lancet Oncol. 2015;16:795\u2013803.","journal-title":"Lancet Oncol"},{"key":"588_CR44","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/nature14292","volume":"520","author":"C Twyman-Saint Victor","year":"2015","unstructured":"Twyman-Saint Victor C, Rech AJ, Maity A, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015;520:373\u20137.","journal-title":"Nature"},{"key":"588_CR45","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s40425-016-0156-7","volume":"4","author":"J Kang","year":"2016","unstructured":"Kang J, Demaria S, Formenti S. Current clinical trials testing the combination of immunotherapy with radiotherapy. J Immunother Cancer. 2016;4:51.","journal-title":"J Immunother Cancer"},{"key":"588_CR46","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1038\/bjc.2017.142","volume":"116","author":"S Parakh","year":"2017","unstructured":"Parakh S, Park JJ, Mendis S, et al. Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases. Br J Cancer. 2017;116:1558\u201363.","journal-title":"Br J Cancer"},{"key":"588_CR47","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/j.ijrobp.2009.06.006","volume":"77","author":"BJ Blonigen","year":"2010","unstructured":"Blonigen BJ, Steinmetz RD, Levin L, et al. Irradiated volume as a predictor of brain radionecrosis after linear accelerator stereotactic radiosurgery. Int J Radiat Oncol Biol Phys. 2010;77:996\u20131001.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"588_CR48","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/1748-717X-6-48","volume":"15","author":"G Minniti","year":"2011","unstructured":"Minniti G, Clarke E, Lanzetta G, et al. Stereotactic radiosurgery for brain metastases: analysis of outcome and risk of brain radionecrosis. Radiat Oncol. 2011;15(6):48.","journal-title":"Radiat Oncol"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0588-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40425-019-0588-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0588-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T18:46:36Z","timestamp":1663267596000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-019-0588-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,11]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["588"],"URL":"https:\/\/doi.org\/10.1186\/s40425-019-0588-y","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,11]]},"assertion":[{"value":"22 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study approved by the Universit\u00e0 di Roma Sapienza and Ospedale San Pietro Institutional Review Boards as retrospective clinical research. Due to the retrospective nature of the study and use of de-identified data, no consent was needed for the patients described in this series.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"GM has received personal fees from BrainLab, outside the submitted work. The remaining authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"102"}}